Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Now Rated "Hold" by Sell-Side Analysts

Key Points

• Analyst consensus on Lantheus is “Hold”: Eleven of 14 analysts maintain hold ratings, while three recommend buying the stock. The average 12-month price target is $107.44.
• Institutional ownership remains high at 99.06%, with several investors recently initiating or increasing positions, including ABS Investment Management’s approximately $233 million stake.
• Lantheus reported quarterly EPS of $1.55, exceeding the $1.30 consensus estimate, while revenue of $388.18 million rose 2.7% year over year and also topped expectations.

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) have received an average recommendation of "Hold" from the fourteen analysts that are presently covering the firm, MarketBeat reports. Eleven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $107.44.

Several research analysts have weighed in on the stock. Weiss Ratings cut shares of Lantheus from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday, October 15th. TD Cowen cut Lantheus from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. William Blair set a $102.50 target price on Lantheus in a research report on Monday, August 3rd. Leerink Partners set a $102.50 target price on Lantheus in a research note on Monday, August 3rd. Finally, Citizens Jmp reissued a "market outperform" rating and set a $115.00 price target on shares of Lantheus in a report on Monday, June 29th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. ABS Investment Management LLC bought a new stake in shares of Lantheus in the second quarter valued at about $232,974,000. Western Wealth Management LLC acquired a new position in shares of Lantheus in the first quarter valued at about $25,000. USA Financial Formulas acquired a new position in shares of Lantheus in the third quarter valued at about $41,000. Allworth Financial LP bought a new position in Lantheus during the second quarter worth about $49,000. Finally, Bessemer Group Inc. increased its position in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 354 shares during the period. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

Shares of LNTH stock opened at $99.80 on Monday. The company has a fifty day moving average price of $100.30 and a two-hundred day moving average price of $98.75. The stock has a market cap of $6.52 billion, a P/E ratio of 24.11 and a beta of -0.06. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. Lantheus has a one year low of $50.15 and a one year high of $111.86.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The firm had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. During the same quarter in the prior year, the company earned $1.57 earnings per share. The business's revenue for the quarter was up 2.7% compared to the same quarter last year. As a group, equities analysts predict that Lantheus will post 4.54 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company's products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.